Bay Neuropsychiatry

Home
United States
San Francisco, CA
Bay Neuropsychiatry

Call Directions Website Contact the business

We’re here to help hospitals thrive with compassionate psychiatric staffing, from psychiatrists and NPs to psychologists, behaviorists and neuropsychologists.

With proven CMS review support and and turning struggling units into success stories.

11/10/2026

𝗨𝗹𝘁𝗿𝗮𝘀𝗼𝘂𝗻𝗱 𝗦𝘁𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻: 𝗖𝗼𝘂𝗹𝗱 𝗜𝘁 𝗘𝗮𝘀𝗲 𝗗𝗲𝗹𝘂𝘀𝗶𝗼𝗻𝘀?
Could targeted ultrasound help reduce the distress associated with delusions?

In a small trial, researchers surveyed participants with schizophrenia after targeted ultrasound stimulation (TUS) about how strongly they believed their delusions and how much stress they caused. Compared with placebo treatment, ultrasound stimulation was associated with less severe delusions over the following week.

The researchers propose that ultrasound may have influenced activity in a deep brain circuit involved in delusions, possibly through longer-lasting changes in brain connections.

The ultrasound therapy also came with mild side effects, such as fatigue and headache. The findings are very preliminary: only 10 people took part, and the study tested a single session over one week. Larger studies with repeated sessions and better confirmation of targeting are needed.

Read the research here: https://www.nature.com/articles/s44384-026-00076-3

11/09/2026

𝗗𝗼𝗲𝘀 𝘆𝗼𝘂𝗿 𝗗𝗡𝗔 𝗰𝗵𝗮𝗻𝗴𝗲 𝗱𝘂𝗿𝗶𝗻𝗴 𝗮𝗻𝘁𝗶𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁?
A study conducted by Svenja Müller and colleagues tracked DNA methylation in people with MDD during their 8 weeks of antidepressant treatment. They found changes in DNA methylation that affect how genes are switched on or off. It changes gene activity but not the DNA code itself.

The research found some methylation pattern changes during antidepressant treatment, and some of these changes are also linked with depression symptoms. They also identified changes near genes that are linked to brain adaptability and inflammation.

It's still early research, and these DNA changes can’t yet tell doctors which medication will work for someone or that the changes caused people to improve.

Read more here: https://www.nature.com/articles/s41380-026-03945-1

11/08/2026

𝗔 𝗡𝗮𝘀𝗮𝗹 𝗦𝗽𝗿𝗮𝘆 𝗳𝗼𝗿 𝗗𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻?

We often use intranasal sprays for allergies, nasal congestion, and sinus problems. What if I told you that there is a psychedelic nasal spray that may improve depression?

In a study conducted by David Feifel, MD, PhD, and colleagues, 193 adults showed reductions in depression scores after receiving a single dose of intranasal mebufotenin benzoate.

According to the study's findings, the intranasal spray produced rapid, robust, and durable reductions in depressive symptoms. This may improve patient treatment access and convenience while potentially resulting in shorter monitoring periods and fewer clinic visits.

Could this represent a new direction in depression treatment?

Read the research here:

https://jamanetwork.com/journals/jama/article-abstract/2855796

𝑁𝑜𝑡𝑒: 𝑀𝑒𝑓𝑢𝑏𝑜𝑡𝑒𝑛𝑖𝑛 𝑏𝑒𝑛𝑧𝑜𝑎𝑡𝑒 𝑟𝑒𝑚𝑎𝑖𝑛𝑠 𝑖𝑛𝑣𝑒𝑠𝑡𝑖𝑔𝑎𝑡𝑖𝑜𝑛𝑎𝑙; 𝑓𝑢𝑟𝑡ℎ𝑒𝑟 𝑟𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑖𝑠 𝑛𝑒𝑒𝑑𝑒𝑑 𝑡𝑜 𝑒𝑠𝑡𝑎𝑏𝑙𝑖𝑠ℎ 𝑖𝑡𝑠 𝑠𝑎𝑓𝑒𝑡𝑦 𝑎𝑛𝑑 𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠.

11/07/2026

𝗘𝗖𝗧: 𝗪𝗵𝘆 𝗜𝘀 𝗢𝗻𝗲 𝗼𝗳 𝗣𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝘆’𝘀 𝗠𝗼𝘀𝘁 𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗦𝘁𝗶𝗹𝗹 𝗨𝗻𝗱𝗲𝗿𝘂𝘁𝗶𝗹𝗶𝘇𝗲𝗱?
We have a treatment capable of producing substantial improvement in severe depression, yet many patients never receive a referral. Why?

Electroconvulsive therapy remains an important treatment for severe depression, particularly in patients with psychotic features, catatonia, or an urgent need for clinical improvement.

Modern ECT is performed under general anesthesia with muscle relaxation and physiological monitoring. Yet misconceptions about the procedure, concerns about cognitive adverse effects, and limited access continue to influence treatment decisions.

For clinicians, the question is not whether ECT has risks; it does, but whether those risks are being weighed appropriately against the consequences of prolonged, severe psychiatric illness.

𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻: Are we waiting too long to refer patients for ECT, particularly after multiple unsuccessful medication trials?

Read the research: https://pubmed.ncbi.nlm.nih.gov/38265758/

11/06/2026

𝗖𝗼𝘂𝗹𝗱 𝗮 𝘀𝗶𝗻𝗴𝗹𝗲 𝗽𝘀𝘆𝗰𝗵𝗲𝗱𝗲𝗹𝗶𝗰 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗽𝗿𝗼𝗱𝘂𝗰𝗲 𝗮𝗻𝘁𝗶𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗹𝗮𝘀𝘁𝗶𝗻𝗴 𝘄𝗲𝗲𝗸𝘀?
A randomized feasibility trial investigated a single 25 mg dose of psilocybin and reported improvements in depressive symptoms over subsequent weeks.

The possibility of a sustained therapeutic response after limited drug exposure is compelling, particularly when compared with medications requiring daily administration.
But important questions remain.

How durable are these effects? How much benefit is attributable to the medication versus psychological support and treatment expectations? And which patients are most likely to respond? Feasibility studies are important early steps, but they cannot establish routine clinical effectiveness.

Clinical discussion: What evidence would you need before considering psilocybin a viable treatment option for patients with treatment-resistant depression?

Read the research: https://www.nature.com/articles/s41591-026-04541-0

11/05/2026

𝐖𝐡𝐚𝐭 𝐡𝐚𝐩𝐩𝐞𝐧𝐬 𝐰𝐡𝐞𝐧 𝐲𝐨𝐮 𝐰𝐚𝐭𝐜𝐡 𝐚 𝐦𝐨𝐯𝐢𝐞 𝐰𝐡𝐢𝐥𝐞 𝐲𝐨𝐮𝐫 𝐛𝐫𝐚𝐢𝐧 𝐢𝐬 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐢𝐧𝐠 𝐭𝐡𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐬 𝐨𝐟 𝐩𝐬𝐢𝐥𝐨𝐜𝐲𝐛𝐢𝐧?

A 2026 study published in Nature showed how psilocybin changes brain activity in different experiences, including meditation, listening to music, and watching a movie. Researchers looked at how the brain responds in these different settings and how those experiences are felt by the people taking part in it.

𝐎𝐧𝐞 𝐬𝐭𝐫𝐢𝐤𝐢𝐧𝐠 𝐟𝐢𝐧𝐝𝐢𝐧𝐠: half of the participants described their experience as among the most meaningful of their lives.

🔬 Read the original research: https://www.nature.com/articles/s41586-026-10910-z

11/04/2026

𝐂𝐚𝐧 𝐖𝐞 𝐇𝐞𝐚𝐫 𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐈𝐭?
What if subtle changes in speech could help identify perinatal depression or anxiety?

Researchers analyzed clinical interview recordings from 146 pregnant participants to investigate whether speech characteristics could predict major depressive disorder and generalized anxiety disorder. The findings suggest that speech-derived features may have potential as additional screening signals.

Could voice analysis eventually complement conventional screening instruments such as the EPDS and GAD-7? And could it identify patients whose symptoms are missed during routine prenatal care? Clinical discussion: Would you trust AI-based speech assessment as an adjunct to psychiatric screening? What level of validation would you require?

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡: https://www.psychiatrist.com/jcp/speech-multivariable-prediction-models-major-depressive-disorder-generalized-anxiety-disorder-pregnancy/

11/03/2026

𝐊𝐞𝐭𝐚𝐦𝐢𝐧𝐞: 𝐈𝐬 𝐈𝐭𝐬 𝐀𝐧𝐭𝐢𝐝𝐞𝐩𝐫𝐞𝐬𝐬𝐚𝐧𝐭 𝐄𝐟𝐟𝐞𝐜𝐭 𝐀𝐛𝐨𝐮𝐭 𝐌𝐨𝐫𝐞 𝐓𝐡𝐚𝐧 𝐆𝐥𝐮𝐭𝐚𝐦𝐚𝐭𝐞?

Could ketamine change how the brain responds to negative experiences?

We often discuss ketamine’s antidepressant effects in terms of NMDA receptor antagonism, glutamatergic signaling, and downstream neuroplasticity. But research involving 70 healthy adults suggests another potentially relevant mechanism: reduced activity in the habenula, a brain region implicated in processing negative outcomes.

Could ketamine’s effects on negative-outcome processing help explain some of its
rapid antidepressant properties?

𝐀𝐧 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐥𝐢𝐦𝐢𝐭𝐚𝐭𝐢𝐨𝐧: Findings in healthy volunteers do not establish that habenular modulation mediates clinical antidepressant response.

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧: Could changes in negative reinforcement learning become a useful biomarker for ketamine response?

Read the research: https://doi.org/10.1016/j.cub.2026.08.044

11/02/2026

𝐓𝐌𝐒: 𝐀𝐫𝐞 𝐖𝐞 𝐓𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐖𝐫𝐨𝐧𝐠 𝐂𝐢𝐫𝐜𝐮𝐢𝐭𝐬?
Two patients with depression. Two very different symptom profiles. Should they receive the same TMS protocol?

Emerging research suggests that targeting different neural circuits may produce different effects on depressive and anxiety symptoms. This raises an important question for clinicians: Should TMS treatment selection be driven by diagnosis alone or by the specific symptoms and neural networks involved?

As precision neuromodulation advances, the traditional one-protocol-fits-all approach deserves closer examination.

𝑪𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝒅𝒊𝒔𝒄𝒖𝒔𝒔𝒊𝒐𝒏: Could symptom-specific targeting meaningfully improve outcomes for patients with anxious depression or treatment-resistant depression?

Read the research: https://www.nature.com/articles/s41380-026-03535-1

09/05/2025

A quick brainwave test may revolutionize Alzheimer’s detection. Researchers from Bath and Bristol have successfully trialed Fastball EEG, a 3-minute test that uses brain responses to images to identify early memory decline, even before clinical symptoms are obvious. For the first time, this tool was tested in patients’ homes with reliable results, proving its potential as a low-cost, widely available screening method. With breakthrough Alzheimer’s drugs like Donanemab and Lecanemab most effective in the earliest stages, tools like Fastball could help deliver faster diagnoses and open the door to earlier treatment.

Read the full announcement here: https://www.bath.ac.uk/announcements/early-alzheimers-brainwave-test-detects-memory-decline-years-before-diagnosis/

Address

San Francisco Bay Area, Peninsula, & East Bay Clients
San Francisco, CA
94123

Telephone

+16505024589

Website

https://www.bayneuropsychiatry.com/

Alerts

Be the first to know and let us send you an email when Bay Neuropsychiatry posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.